FDA panel to review Wyeth’s Viviant
Executive Summary
FDA will convene an advisory committee in July to review Wyeth's Viviant (bazedoxifene) for both the treatment and prevention of osteoporosis, the company announces Jan. 31. Wyeth will meet with FDA in February to discuss issues raised in a December "approvable" letter for the prevention indication. During fourth quarter earnings call, Wyeth President-Pharmaceuticals Joe Mahady says agency concerns involve incidents of stroke and thrombotic events as well as data collection at one of the study sites. Firm expects a May FDA action date on the drug to change given the timing of the panel review...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.